Positron Emission Tomography and Ultrasonography: A Comparative Retrospective Study Assessing the Diagnostic Validity in Lymph Node Metastases of Malignant Melanoma

Archives of Dermatology

Volumn 131, Issue 12, 1995, Pages 1394-1398

  Blessing, Charlotte ^a   Feine, Ulrich ^a   Geiger, Livia ^a   Carl, Marina ^a   Rassner, Gernot ^a   Fierlbeck, Gerhard ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; CICATRIX; COMPARATIVE STUDY; COSTS AND COST ANALYSIS; DEOXYGLUCOSE; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUDEOXYGLUCOSE F 18; FLUORINE RADIOISOTOPES; FOLLOW-UP STUDIES; HUMAN; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGE; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SUPPORT, NON-U.S. GOV'T; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0028863091     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1995.01690240048008     Document Type: Article

References (24)

1. 1. Ledermann JA. Medical and radiation therapy. Lancet. 1992; 340: 948-949.
2. 2. Tillman DM, Aitchison T, Watt DC, MacKie RM. Stage II melanoma in the west of Scotland, 1976-1985: prognostic factors for survival. Eur J Cancer. 1991; 27: 870-876.
3. 3. Balch CM. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol. 1988; 6: 163-172.
4. 4. Gritzmann N, Czembirek H, Hajek P, Türk R, Karnel F, Frühwald F. Sonographie bei zervikalen Lymphknotenmetastasen. Radiologie. 1987; 27: 118-122.
5. 5. Stutte H, Eibe S, Rassner G. Lymphknotensonographie in der Nachsorge des malignen Melanoms. Hautarzt. 1989; 40: 344-349.
6. 6. Prayer L, Winkelbauer F, Gritzmann N, Weislein H, Helmer M, Pehamberger H. Untersuchung der primären Lymphknotenstationen beim malignen Melanom mittels hochauflösender real-time Sonographie: Stellenwert und Indikation. Fortschr Rontgenstr. 1989; 151: 294-297.
7. 7. Fornage BD, Lorigan JG. Sonographic detection and fine-needle aspiration biopsy of nonpalpable recurrent or metastatic melanoma in subcutaneous tissues. J Ultrasound Med. 1989; 8: 421-424.
8. 8. Feinendegen LE. Contributions of nuclear medicine to the therapy of malignant tumors. J Cancer Res Clin Oncol. 1993; 119: 320-322.
9. 9. Messa C, Choi Y, Hoh CK, et al. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr. 1992; 16: 684-689.
10. 10. Warburg O. The Metabolism of Tumors. New York, NY: Richard R Smith Inc; 1931: 129-169.
11. 11. Kern KA. [14C] Deoxyglucose uptake and imaging in malignant melanoma. J Surg Res. 1991; 50: 643-647.
12. 12. Wahl RL, Kaminski MS, Ethier SP, Hutchins GD. The potential of 2-deoxy-[18F] fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med. 1990; 31: 1831-1835.
13. 13. Rozental JM, Levine RL, Mehta MP, et al. Early changes in tumor metabolism after treatment: the effects of stereotactic radiotherapy. Int J Radiol Oncol Biol Phys. 1991; 20: 1053-1060.
14. 14. Chaiken L, Rege S, Hoh C, et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys. 1993; 27: 455-464.
15. 15. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med. 1993; 34: 1420-1427.
16. 16. Böni R, Huch Böni R, Steinert H, et al. Early detection of melanoma metastasis by whole-body positron emission tomography (PET) using [18F] FDG: important factors for therapeutic procedures and prognosis. In: Program and abstracts of the International Meeting of the European Academy of Dermatology and Venerology and the Hellenic Society of Dermatology and Venerology; October 14-17 1994; Crete, Greece.
17. 17. Scott AM, Larson SM. Tumor imaging and therapy. Radiol Clin North Am. 1993; 31: 859-879.
18. 18. Wienhard K, Wagner R, Heiss WD. PET, Grundlagen und Anwendungen der Positronen-Emissions-Tomographie. New York, NY: Springer-Verlag NY Inc; 1989.
19. 19. Reisser C, Haberkorn U, Strauss LG. The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors. J Otolaryngol. 1993; 22: 231-238.
20. 20. Sokoloff L. Circulation and metabolism of the brain. In: Siegel GJ, Albers RW, Katzmann R, Agranoff BW, eds. Basic Neurochemistry. 2nd ed. Boston, Mass: Little Brown & Co Inc; 1976: 388-413.
21. 21. Gumppenberg RM, Strauss LG. Klinische Indikationen für die PET in der Onkologie. Schweiz Rundsch Med Prax. 1993; 82: 919-923.
22. 22. Haberkorn U, Strauss LG, Dimitriakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med. 1993; 34: 12-17.
23. 23. Tilgen W, Strauss LG, Metz R, Helus F, Zierott U, Haberkorn U. Die Positronemissionstomographie: ein neues Verfahren zur Individualisierung und Optimierung der Diagnostik und Therapie bei Melanompatienten. In: Burg G, Hartmann AA, Konz B, eds. Onkologische Dermatologie. New York, NY: Springer-Verlag NY Inc; 1993: 121-128.
24. 24. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med. 1991: 32: 1485-1490.